Visfatin, human recombinant, BioVisionSupplier: BioVision
4907-1000 4907-50 4907-10
10007-292EA 3576.88 USD10007-292 10007-294 10007-290
Visfatin, human recombinant, BioVision
Proteins and Peptides
>95% Pure active Recombinant human Visfatin.
Mimics insulin effects in differentiating 3T3-L1 cells.
Visfatin exerts insulin-mimetic effects that are dose-dependent and quantitatively similar to those of insulin in stimulating muscle and adipocyte glucose transport, and in inhibiting hepatocyte glucose production. Intravenous injection of recombinant visfatin in mice decreased plasma glucose in a dose-dependent fashion. In keeping with its insulin-mimetic effects, visfatin was as effective as insulin in reducing hyperglycemia in insulin-deficient diabetic mice. Visfatin was also found to be bound to and activate insulin receptor, causing receptor phosphorylation and the activation of downstream signaling molecules. However, visfatin and insulin did not compete for binding to the insulin receptor, indicating that the two proteins were recognized by different regions of the receptor. Thus, visfatin might play a role in glucose homeostasis and dysregulation in biosynthesis or signal transduction, and might contribute to the pathogenesis of diabetes.